Meeting
2023 ASCO Annual Meeting
Abemaciclib in recurrent/metastatic head and neck squamous cell carcinoma (RM-HNSCC) harboring CDKN2A loss, and/or CCND1 and/or CDK6 amplification: A phase II multicenter trial.
Authors
Jerome Fayette
Centre Léon Bérard, Lyon, France
Jerome Fayette , Esma Saada-Bouzid , Claire Cropet , Amaury Daste , Isabelle Treilleux , Daniel Pissaloux , Frank Pilleul , Charles Mastier , Eve-Marie Neidhardt , Andy Karabajakian , Elodie Grinand , Romaine Mayet , Mathilde Bernardin , Clothilde Celse , Gwenaelle Garin , David Pérol
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Head and Neck Cancer
Track
Head and Neck Cancer
Sub Track
Advanced/Metastatic Disease
Clinical Trial Registration Number
NCT03356223
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 6044)
DOI
10.1200/JCO.2023.41.16_suppl.6044
Abstract #
6044
Poster Bd #
36
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
An international, multicenter, randomized, double-blind, placebo-controlled, parallel-group phase 2 study of palbociclib (an oral CDK4/6 inhibitor) plus cetuximab in patients with recurrent/metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN).
First Author: Bhumsuk Keam
Poster
2023 ASCO Annual Meeting
Correlation of CDKN2A genomic alterations with tumor response to palbociclib given before chemoradiation therapy (CRT) to patients with human papillomavirus (HPV)-negative, locally advanced head and neck squamous-cell carcinoma (LA-HNSCC): A single-arm, phase 2 trial.
First Author: Peter John Oppelt
Poster
2022 ASCO Annual Meeting
Molecular alterations associated with rapid progression following CDK4/6 inhibitors (CDKi) in metastatic hormone receptor–positive breast cancer (mHRBC).
First Author: Malinda T West
Poster
2021 ASCO Annual Meeting
Preliminary results of the abemaciclib arm in the Individualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT): A phase II platform trial using Bayesian adaptive randomization.
First Author: Eudocia Quant Lee